These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14696561)

  • 41. [Simple, safe and effective. New protease inhibitor means progress].
    MMW Fortschr Med; 2002 Dec; 144(49):52-3. PubMed ID: 12577744
    [No Abstract]   [Full Text] [Related]  

  • 42. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    Rekić D; Clewe O; Röshammar D; Flamholc L; Sönnerborg A; Ormaasen V; Gisslén M; Abelö A; Ashton M
    AAPS J; 2011 Dec; 13(4):598-605. PubMed ID: 21913053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atazanavir.
    Orrick JJ; Steinhart CR
    Ann Pharmacother; 2004 Oct; 38(10):1664-74. PubMed ID: 15353575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
    Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reviving protease inhibitors: new data and more options.
    Murphy RL
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
    [No Abstract]   [Full Text] [Related]  

  • 49. Knee avascular necrosis in HIV patient.
    Declet VR; Salas AS
    Bol Asoc Med P R; 2015; 107(2):24-6. PubMed ID: 26434077
    [No Abstract]   [Full Text] [Related]  

  • 50. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atazanavir: improving the HIV protease inhibitor class.
    Becker S
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):403-13. PubMed ID: 15482137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
    Guffanti M; Caumo A; Galli L; Bigoloni A; Galli A; Dagba G; Danise A; Luzi L; Lazzarin A; Castagna A
    Eur J Endocrinol; 2007 Apr; 156(4):503-9. PubMed ID: 17389467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
    López-Cortés LF
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy of atazanavir in rescue therapy].
    Portilla J; Boix V; Merino E; Reus S
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():22-7. PubMed ID: 20116613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
    TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
    [No Abstract]   [Full Text] [Related]  

  • 57. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
    Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
    Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New protease inhibitor atazanavir (Reyataz) approved.
    AIDS Treat News; 2003 Jun; (392):3. PubMed ID: 12913956
    [No Abstract]   [Full Text] [Related]  

  • 60. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
    Barrail-Tran A; Mentré F; Cosson C; Piketty C; Chazallon C; Gérard L; Girard PM; Taburet AM
    Antimicrob Agents Chemother; 2010 Feb; 54(2):614-9. PubMed ID: 19995932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.